GlassScriptPhysician profile
Mohsin K Malik
NPI 1376864371
$16,309.09
in general payments reported to CMS, 2019-2025
33 companies · $3,805 in 2025
The $3,805 reported for 2025 was more than what 88% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,369 · 2020: $491 · 2021: $1,389 · 2022: $2,583 · 2023: $3,139 · 2024: $3,533 · 2025: $3,805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,093.18 |
| Education | $384.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,967.95 | 2019-2025 | |
| Pfizer INC. | $1,443.87 | 2019-2025 | |
| Amgen INC. | $1,439.20 | 2019-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $1,297.44 | 2019-2025 | Dupixent, Libtayo |
| Ucb, INC. | $1,261.49 | 2021-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $1,050.88 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Leo Pharma INC. | $881.62 | 2019-2025 | Adbry, Anzupgo |
| Incyte Corporation | $792.42 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $699.59 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $675.10 | 2022-2024 | Sotyktu |
| Genzyme Corporation | $632.85 | 2019-2025 | |
| Lilly USA, LLC | $618.49 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $515.70 | 2019-2025 | Absorica Ld, Winlevi |
| Arcutis Biotherapeutics, INC. | $427.70 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $397.77 | 2021-2025 | Nemluvio, Aklief, Oracea |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $220.45 | 2019-2023 | Jublia |
| Dermavant Sciences, INC. | $165.62 | 2023-2024 | Vtama |
| Mayne Pharma Commercial LLC | $147.31 | 2019-2025 | |
| Sebela Pharmaceuticals INC. | $109.53 | 2021-2023 | Naftin |
| Organon LLC | $70.65 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.83 | 2024-2025 | Spevigo |
| Celgene Corporation | $59.29 | 2019 | |
| Lnhc, INC | $53.20 | 2025 | Zelsuvmi |
| Almirall LLC | $51.98 | 2019-2022 | |
| Verrica Pharmaceuticals INC. | $47.78 | 2024-2025 | Ycanth |
| Botanix Sb INC | $47.49 | 2025 | Sofdra |
| Journey Medical Corporation | $44.01 | 2022-2024 | |
| Epi Health, LLC | $38.13 | 2022 | |
| Genentech USA, INC. | $22.76 | 2019 | |
| Sanofi-Aventis U.S. LLC | $18.69 | 2019 | |
| Biofrontera INC. | $18.32 | 2025 | Ameluz |
| Dermira, INC. | $16.37 | 2020 | |
| Gilead Sciences, INC. | $15.61 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohsin Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.